Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7RJXL)

• Drug Name: Imatinib Drug Info
• Synonyms: Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[1]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[2]
Choroidal neovascularization	9B76	Approved	[2]
Chronic eosinophilic leukemia		Approved	[2]
Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Chronic myeloid leukaemia	2A20	Approved	[4]
Dermatofibrosarcoma protuberans		Approved	[2]
Gastrointestinal stromal tumour	2B5B	Approved	[2]
Leukemia		Approved	[2]
Malignant peripheral nerve sheath tumor		Approved	[2]
Myeloproliferative neoplasm	2A20	Approved	[2]
Pulmonary hypertension	BB01	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[5]
Intestinal cancer	2C0Z	Phase 3	[3]
Lung cancer	2C25.0	Phase 2	[3]
Idiopathic hypereosinophilic syndrome		Investigative	[2]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[6]
Scleroderma	4A42	Investigative	[2]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[6]
Systemic mastocytosis	2A21.0	Investigative	[7]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 5291
  ChEBI ID: CHEMBL941
  CAS Number: CAS 152459-95-5
  TTD Drug ID: DM7RJXL
  VARIDT Drug ID: DR00032
  INTEDE Drug ID: DR0858
  ACDINA Drug ID: D00324

Molecule-Related Drug Atlas

Drug(s) Targeting Fusion protein Bcr-Abl (Bcr-Abl)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[8]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[30]
Asciminib	DM7EVUF	Chronic myeloid leukaemia	2A20	Approved	[31]
Radotinib	DMWA74Y	leukaemia	2A60-2B33	Phase 3	[32]
ABL 001	DMMF5K4	Chronic myeloid leukaemia	2A20	Phase 3	[33]
ICLUSIG	DM1SQSE	Acute lymphoblastic leukaemia	2A85	Phase 3	[34]
Bafetinib	DM7586F	Bone disease	FC0Z	Phase 2	[35]
AN-019	DMJ7QP8	Chronic myelogenous leukaemia	2A20.0	Phase 2	[36]
HQP1351	DMQ30X2	Chronic myeloid leukaemia	2A20	Phase 2	[37]
NPB-001-056	DM78KMT	Chronic myelogenous leukaemia	2A20.0	Phase 1/2	[38]

Drug(s) Targeting Platelet-derived growth factor receptor (PDGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[39]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[40]
CT-102	DMB8PF3	Diabetic foot ulcer	BD54	Approved	[41]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[42]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[8]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[8]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[43]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[44]
PMID25623274-Compound-WO2014132220C2	DMXEZWP	Pulmonary arterial hypertension	BB01.0	Patented	[45]
PMID25623274-Compound-WO2014132220C1	DMA2IMQ	Pulmonary arterial hypertension	BB01.0	Patented	[45]

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[46]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[47]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[1]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[1]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[39]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[48]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[49]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[50]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[51]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[52]

Drug(s) Targeting HUMAN fusion protein Bcr-Abl (Bcr-Abl)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[6]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[53]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[54]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[55]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[56]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[55]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[57]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[55]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[58]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[59]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[60]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[61]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[62]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[64]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[65]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[66]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[65]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[67]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[68]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[70]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[71]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[12]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[72]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[73]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[74]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[75]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[72]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[76]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[77]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[78]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[79]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[53]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[80]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[81]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[82]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[83]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[84]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[53]

Drug(s) Transported By Organic anion transporting polypeptide 1A2 (SLCO1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[86]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[87]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[88]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[89]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[90]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[91]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[92]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[93]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[94]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[95]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[96]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[97]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[12]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[98]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[73]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[75]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[99]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[75]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[100]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[101]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[102]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[103]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[104]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[105]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[106]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[107]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[102]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[15]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[108]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[109]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[110]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[111]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[112]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[113]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[106]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[114]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[115]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[116]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[117]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[118]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[119]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[120]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[105]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[121]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[122]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[123]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[124]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[125]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[126]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[127]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[128]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[129]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[130]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[131]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[132]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[133]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[20]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[134]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[135]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[136]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[137]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[20]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[20]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[20]
Metronidazole	DMTIVEN	Abscess		Approved	[138]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[139]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[109]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[19]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[136]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[140]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[141]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[142]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[19]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[143]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[144]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[145]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[146]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[147]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[148]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[136]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[136]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[149]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[150]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[151]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[153]

Drug(s) Metabolized By Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[154]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[15]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[15]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[15]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[15]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[15]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[15]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[15]
Terbinafine	DMI6HUW	Fungal infection	1F29-1F2F	Approved	[15]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[155]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[155]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[156]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[157]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[158]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[159]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[160]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[161]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[162]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[163]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[164]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[165]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[166]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[167]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[168]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[169]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[170]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[171]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[172]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[170]

Drug(s) Affected By Aldehyde dehydrogenase, mitochondrial (ALDH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[176]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[177]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[179]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[180]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[182]

Drug(s) Affected By Eukaryotic translation initiation factor 4E (EIF4E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[183]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[184]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[185]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[186]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[187]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[188]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[187]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[189]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[190]

Drug(s) Affected By Fructose-bisphosphate aldolase C (ALDOC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[191]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[192]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[194]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[195]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[197]

Drug(s) Affected By Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[185]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[198]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[180]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[199]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[189]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[200]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[201]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[202]

Drug(s) Affected By Eukaryotic translation initiation factor 4B (EIF4B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[203]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[204]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[180]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[205]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[206]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[207]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[208]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[203]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[209]

Drug(s) Affected By Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[210]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[211]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[212]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[213]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[214]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[215]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[216]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[217]

Drug(s) Affected By G1/S-specific cyclin-D3 (CCND3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[218]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[219]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[220]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[221]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[222]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[223]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[224]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[225]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[226]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]

Drug(s) Affected By Hexokinase-4 (GCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[228]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[229]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[230]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[229]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[231]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[232]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[233]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[234]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[235]

Drug(s) Affected By Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[236]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[237]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[238]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[239]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[189]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[240]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[241]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[242]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[243]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[244]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[29]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[245]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[245]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[246]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[29]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[245]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[247]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[29]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[248]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[29]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[249]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[250]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[251]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[252]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[253]
Selenium	DM25CGV	N. A.	N. A.	Approved	[254]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[249]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[255]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[256]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[255]

Drug(s) Affected By Autophagy-related protein 13 (ATG13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[258]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[259]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[260]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[261]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[262]
cycloheximide	DMGDA3C	Discovery agent	N.A.	Investigative	[263]

Drug(s) Affected By Keratin, type I cytoskeletal 14 (KRT14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[264]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[265]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[265]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[266]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[267]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[265]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[268]
Methamphetamine	DMPM4SK	Anxiety		Approved	[269]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[270]

Drug(s) Affected By Heat shock protein beta-1 (HSPB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[271]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[272]
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[273]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[274]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[275]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[276]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[277]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]

Drug(s) Affected By Tyrosine-protein kinase Lck (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[261]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[203]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[278]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[185]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[279]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[280]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[281]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[282]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[200]

Drug(s) Affected By ATP-dependent 6-phosphofructokinase, muscle type (PFKM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[283]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[22]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[243]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[208]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[284]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[285]
Bardoxolone methyl	DMODA2X	Mixed connective tissue disease	4A43.3	Phase 3	[286]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[287]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[288]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[289]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[290]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[291]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[292]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[293]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[292]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[294]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[295]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[296]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[297]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[298]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[299]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[300]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[301]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[302]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[303]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[304]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[305]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[303]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[306]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[307]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[308]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[191]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[309]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[310]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[309]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[194]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[225]

Drug(s) Affected By Keratin, type II cytoskeletal 5 (KRT5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[264]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[265]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[265]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[311]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[312]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[265]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[268]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[313]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[314]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[315]
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[316]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[317]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[318]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[319]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[320]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[321]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[322]

Drug(s) Affected By Transcription factor EB (TFEB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[323]
Prochlorperazine	DM53SRA	Nausea	MD90	Approved	[323]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[324]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[230]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[180]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[325]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[190]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[277]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[326]

Drug(s) Affected By Insulin-like growth factor-binding protein 4 (IGFBP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[327]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[328]
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[256]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[329]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[185]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[330]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[331]

Drug(s) Affected By Interleukin-4 receptor subunit alpha (IL4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[206]
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[332]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[333]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[334]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[335]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[336]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[337]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[338]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[339]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[340]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[341]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[342]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[343]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[344]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[345]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[346]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[347]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[348]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[349]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[340]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[350]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[351]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[352]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[339]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[157]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[251]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[342]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[343]

Drug(s) Affected By Catenin beta-1 (CTNNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[353]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[354]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[355]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[306]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[356]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[357]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[358]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[359]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[360]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[361]

Drug(s) Affected By Crk-like protein (CRKL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[362]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[363]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[364]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[365]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[208]
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[366]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[201]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[367]
PMID25656651-Compound-5	DMAI95U	Chronic myeloid leukaemia	2A20	Patented	[368]

Drug(s) Affected By Small ribosomal subunit protein eS6 (RPS6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[369]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[256]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[370]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[371]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[266]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[372]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[373]
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[374]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[375]

Drug(s) Affected By Heat shock factor protein 1 (HSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[376]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[377]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[377]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[378]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[379]
Ceftazidime	DM41GRA	Bacteremia	1A73	Approved	[377]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[377]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[377]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[377]

Drug(s) Affected By Transcription factor p65 (RELA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[251]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[380]
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[381]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[382]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[383]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[384]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[203]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[385]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[386]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[387]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[291]
Selenium	DM25CGV	N. A.	N. A.	Approved	[257]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[388]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[332]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[389]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[390]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[391]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[392]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[393]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[394]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[395]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[396]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[397]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[394]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[398]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[399]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[394]

Drug(s) Affected By NGFI-A-binding protein 2 (NAB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[395]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[206]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[400]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[331]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[338]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[401]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[402]
Bortezomib	DMNO38U	Leukemia		Approved	[403]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[189]

Drug(s) Affected By TRAF family member-associated NF-kappa-B activator (TANK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[354]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[216]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[404]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[405]
Bortezomib	DMNO38U	Leukemia		Approved	[403]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[406]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[407]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[408]

Drug(s) Affected By NACHT, LRR and PYD domains-containing protein 3 (NLRP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[251]
Selenium	DM25CGV	N. A.	N. A.	Approved	[409]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[410]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[411]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[216]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[412]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[413]
Atropine	DMEN6X7	Organophosphate poisoning	NE6Z	Approved	[414]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[414]

Drug(s) Affected By Bile acid receptor (NR1H4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[396]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[415]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[416]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[417]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[213]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[415]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[416]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[178]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[418]

Drug(s) Affected By Docking protein 1 (DOK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[216]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[419]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[258]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[364]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[208]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[257]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[420]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[421]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[260]

Drug(s) Affected By Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[422]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[210]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[332]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[423]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[213]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[424]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[324]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[425]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[426]

Drug(s) Affected By Transcription factor SOX-17 (SOX17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[427]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[427]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[427]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[427]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[427]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[428]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[429]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[427]
Ziprasidone	DMM58JY	Bipolar disorder	6A60	Approved	[427]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[430]

Drug(s) Affected By V-type proton ATPase subunit H (ATP6V1H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[331]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[189]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[431]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[432]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[367]
PP-242	DM2348V	Discovery agent	N.A.	Investigative	[433]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[434]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[404]

Drug(s) Affected By LYR motif-containing protein 9 (LYRM9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[435]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[180]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[436]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[258]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[233]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[208]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[437]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[438]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[439]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[235]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[440]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[441]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[442]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[291]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[443]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[444]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[445]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[446]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[447]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[448]

Drug(s) Affected By Bcl-2-like protein 11 (BCL2L11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[449]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[450]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[451]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[452]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[453]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[454]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[455]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[456]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[216]

Drug(s) Affected By Tyrosine-protein kinase Lyn (LYN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[261]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[274]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[185]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[454]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[279]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[457]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[180]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[181]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[429]

Drug(s) Affected By Serine/threonine-protein kinase PLK1 (PLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[218]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[458]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[459]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[460]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[461]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[462]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[336]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[336]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[331]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[8]
Mcl-1 messenger RNA (MCL-1 mRNA)	TTN6ORK	MCL1_HUMAN	Not Available	[7]
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Inhibitor	[8]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[8]
HUMAN fusion protein Bcr-Abl (Bcr-Abl)	TTE63HY	BCR_HUMAN/ABL1_HUMAN	Inhibitor	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[10]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[12]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[14]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[15]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[18]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[19]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[20]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[15]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldehyde dehydrogenase, mitochondrial (ALDH2)	OTKJ9I3N	ALDH2_HUMAN	Gene/Protein Processing	[21]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM)	OT1QY9JM	PFKAM_HUMAN	Gene/Protein Processing	[22]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[23]
Autophagy-related protein 13 (ATG13)	OTYMHNEJ	ATG13_HUMAN	Post-Translational Modifications	[24]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Drug Response	[25]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[26]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Drug Response	[27]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Gene/Protein Processing	[28]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[29]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[23]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Imatinib FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
• [4] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
• [5] ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
• [6] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [7] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [8] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [9] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [10] Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
• [11] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [12] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [13] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [14] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [15] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [16] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [17] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [18] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [19] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [20] Drug Interactions Flockhart Table
• [21] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [22] Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
• [23] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [24] Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
• [25] Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
• [26] The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
• [27] Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.
• [28] Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
• [29] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [30] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [31] Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
• [32] Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
• [33] ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
• [34] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404.
• [35] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [36] Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
• [37] Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
• [38] NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.
• [39] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [40] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [41] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [42] Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
• [43] National Cancer Institute Drug Dictionary (drug id 695817).
• [44] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [45] Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
• [46] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [47] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [48] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [49] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [50] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [51] National Cancer Institute Drug Dictionary (drug id 452042).
• [52] Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
• [53] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [54] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [55] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [56] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [57] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [58] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [59] Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
• [60] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [61] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [62] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [63] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [64] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [65] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [66] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [67] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [68] Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
• [69] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [70] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [71] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [72] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [73] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [74] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [75] FDA Drug Development and Drug Interactions
• [76] Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
• [77] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [78] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [79] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [80] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [81] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [82] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [83] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [84] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [85] Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
• [86] Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
• [87] Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
• [88] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [89] Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
• [90] Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
• [91] Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
• [92] Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
• [93] Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
• [94] Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
• [95] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [96] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [97] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [98] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [99] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [100] Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
• [101] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [102] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [103] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [104] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [105] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [106] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [107] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [108] Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
• [109] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [110] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [111] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [112] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [113] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [114] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [115] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [116] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [117] Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
• [118] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [119] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [120] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [121] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [122] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [123] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [124] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [125] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [126] Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
• [127] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [128] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [129] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [130] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [131] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [132] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [133] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [134] 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
• [135] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [136] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [137] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [138] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [139] Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
• [140] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [141] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [142] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [143] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [144] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [145] Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
• [146] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [147] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [148] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [149] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [150] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [151] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [152] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [153] In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
• [154] Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
• [155] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [156] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [157] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [158] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [159] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [160] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [161] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [162] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [163] Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer. 2008 Oct 1;123(7):1712-20.
• [164] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [165] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [166] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [167] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [168] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [169] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [170] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [171] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [172] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [173] Metabolomics of oxidative stress: Nrf2 independent depletion of NAD or increases of sugar alcohols. Toxicol Appl Pharmacol. 2022 May 1;442:115949. doi: 10.1016/j.taap.2022.115949. Epub 2022 Feb 25.
• [174] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [175] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [176] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [177] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [178] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [179] The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact. 2012 Jan 5;195(1):52-60.
• [180] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [181] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [182] Differences in the activities of resveratrol and ascorbic acid in protection of ethanol-induced oxidative DNA damage in human peripheral lymphocytes. Food Chem Toxicol. 2012 Feb;50(2):168-74.
• [183] Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2022 Jan 15;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.
• [184] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [185] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [186] Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.
• [187] The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 2007 Dec 1;67(23):11402-10. doi: 10.1158/0008-5472.CAN-07-1792.
• [188] The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
• [189] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [190] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [191] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [192] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [193] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [194] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [195] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [196] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [197] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [198] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [199] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [200] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [201] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [202] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [203] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [204] Characterization of arsenic trioxide resistant clones derived from Jurkat leukemia T cell line: focus on PI3K/Akt signaling pathway. Chem Biol Interact. 2013 Oct 5;205(3):198-211. doi: 10.1016/j.cbi.2013.07.011. Epub 2013 Aug 2.
• [205] Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells. Toxicol Lett. 2011 Sep 10;205(3):341-50. doi: 10.1016/j.toxlet.2011.06.028. Epub 2011 Jul 2.
• [206] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [207] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [208] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [209] Phosphoproteomics reveals resveratrol-dependent inhibition of Akt/mTORC1/S6K1 signaling. J Proteome Res. 2014 Dec 5;13(12):5734-42. doi: 10.1021/pr500714a. Epub 2014 Oct 29.
• [210] Repression of Kisspeptin1 weakens hydrogen peroxide-caused injury in HTR8 cells via adjusting PI3K/AKT/mTOR pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22461. doi: 10.1002/jbt.22461. Epub 2020 Feb 11.
• [211] Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep. 2015 Sep;42(9):1419-29. doi: 10.1007/s11033-015-3921-7. Epub 2015 Aug 27.
• [212] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [213] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [214] Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells. Environ Toxicol. 2021 Sep;36(9):1785-1792. doi: 10.1002/tox.23299. Epub 2021 May 27.
• [215] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [216] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [217] Cantharidin suppresses gastric cancer cell migration/invasion by inhibiting the PI3K/Akt signaling pathway via CCAT1. Chem Biol Interact. 2020 Feb 1;317:108939. doi: 10.1016/j.cbi.2020.108939. Epub 2020 Jan 13.
• [218] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [219] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [220] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [221] Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. J Appl Toxicol. 2013 Dec;33(12):1500-5. doi: 10.1002/jat.2829. Epub 2012 Oct 30.
• [222] Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
• [223] Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res. 2005 Jul 15;65(14):6476-83. doi: 10.1158/0008-5472.CAN-05-0370.
• [224] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [225] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [226] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [227] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [228] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [229] Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016 Jan 15;100:98-111.
• [230] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [231] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [232] Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
• [233] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [234] Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E beta-cells and human islets through a SIRT1-dependent mechanism. J Biol Chem. 2011 Feb 25;286(8):6049-60. doi: 10.1074/jbc.M110.176842. Epub 2010 Dec 16.
• [235] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [236] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [237] Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-B signaling in cervical cancer. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S687-95. doi: 10.1245/s10434-014-3812-5. Epub 2014 Jul 22.
• [238] p38 MAPK/PP2Ac/TTP pathway on the connection of TNF- and caspases activation on hydroquinone-induced apoptosis. Carcinogenesis. 2013 Apr;34(4):818-27. doi: 10.1093/carcin/bgs409. Epub 2013 Jan 3.
• [239] Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. J Biochem Mol Toxicol. 2020 Oct;34(10):e22547. doi: 10.1002/jbt.22547. Epub 2020 Jun 26.
• [240] CREB/Sp1-mediated MCL1 expression and NFB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. Toxicol Appl Pharmacol. 2022 Jan 15;435:115847. doi: 10.1016/j.taap.2021.115847. Epub 2021 Dec 25.
• [241] Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3(1):27-40.
• [242] Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol. 2009 Feb 1;182(3):1500-8. doi: 10.4049/jimmunol.182.3.1500.
• [243] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [244] "Minimalist" cyclopropene-containing photo-cross-linkers suitable for live-cell imaging and affinity-based protein labeling. J Am Chem Soc. 2014 Jul 16;136(28):9990-8. doi: 10.1021/ja502780z. Epub 2014 Jul 3.
• [245] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [246] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [247] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [248] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [249] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [250] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [251] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [252] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [253] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [254] Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther. 2002 May-Jun;1(3):287-90. doi: 10.4161/cbt.83.
• [255] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [256] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [257] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [258] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [259] Label-free quantitative proteomic analysis identifies the oncogenic role of FOXA1 in BaP-transformed 16HBE cells. Toxicol Appl Pharmacol. 2020 Sep 15;403:115160. doi: 10.1016/j.taap.2020.115160. Epub 2020 Jul 25.
• [260] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [261] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [262] Gene expression profile analysis of gallic acid-induced cell death process. Sci Rep. 2021 Aug 18;11(1):16743. doi: 10.1038/s41598-021-96174-1.
• [263] Suppressed translation and ULK1 degradation as potential mechanisms of autophagy limitation under prolonged starvation. Autophagy. 2016 Nov;12(11):2085-2097. doi: 10.1080/15548627.2016.1226733. Epub 2016 Sep 14.
• [264] Activation of PPAR and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One. 2020 Aug 21;15(8):e0237976. doi: 10.1371/journal.pone.0237976. eCollection 2020.
• [265] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [266] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [267] Impact of extracellular folate levels on global gene expression. Mol Pharmacol. 2001 Dec;60(6):1288-95. doi: 10.1124/mol.60.6.1288.
• [268] Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ. 1996 Aug;7(8):997-1004.
• [269] Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
• [270] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [271] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [272] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [273] Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009 Feb 27;256(3):183-90. doi: 10.1016/j.tox.2008.11.016. Epub 2008 Nov 28.
• [274] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [275] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [276] Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
• [277] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [278] Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
• [279] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [280] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [281] Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
• [282] Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
• [283] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [284] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [285] Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie. 2013 Jun;95(6):1336-43. doi: 10.1016/j.biochi.2013.02.013. Epub 2013 Feb 27.
• [286] Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. J Biochem Mol Toxicol. 2022 Nov;36(11):e23192. doi: 10.1002/jbt.23192. Epub 2022 Aug 5.
• [287] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [288] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [289] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [290] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [291] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [292] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [293] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [294] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [295] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [296] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [297] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [298] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [299] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [300] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [301] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [302] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [303] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [304] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [305] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [306] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [307] Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. J Biol Chem. 1990 Nov 25;265(33):20106-16.
• [308] Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun. 2001 Jan 26;280(3):664-74. doi: 10.1006/bbrc.2000.4216.
• [309] Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett. 2009 Jan 30;184(2):81-4. doi: 10.1016/j.toxlet.2008.10.017. Epub 2008 Oct 28.
• [310] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [311] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [312] Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
• [313] The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
• [314] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [315] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [316] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [317] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [318] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [319] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [320] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [321] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [322] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [323] Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. Cell Chem Biol. 2017 Apr 20;24(4):471-480.e4. doi: 10.1016/j.chembiol.2017.03.005. Epub 2017 Mar 30.
• [324] Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway. Biochem Biophys Res Commun. 2018 Jan 29;496(1):167-175. doi: 10.1016/j.bbrc.2018.01.018. Epub 2018 Jan 4.
• [325] A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis. Biochem Pharmacol. 2015 Jun 1;95(3):201-9. doi: 10.1016/j.bcp.2015.03.017. Epub 2015 Apr 13.
• [326] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [327] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [328] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [329] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [330] Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep. 2016 Sep;36(3):1233-42. doi: 10.3892/or.2016.4944. Epub 2016 Jul 15.
• [331] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [332] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [333] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [334] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [335] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [336] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [337] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [338] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [339] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [340] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [341] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [342] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [343] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [344] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [345] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [346] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [347] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [348] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [349] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [350] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [351] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [352] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [353] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [354] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [355] Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
• [356] Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
• [357] Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
• [358] Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
• [359] Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
• [360] Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
• [361] Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):129-36. doi: 10.1016/j.jsbmb.2005.06.008. Epub 2005 Jul 26.
• [362] Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Maywood). 2013 Aug 1;238(8):932-42. doi: 10.1177/1535370213492689. Epub 2013 Jul 24.
• [363] Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.
• [364] Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
• [365] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [366] Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015 Aug 21;6(24):20231-40. doi: 10.18632/oncotarget.4047.
• [367] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [368] A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci. 2015 Jan;143(1):147-55. doi: 10.1093/toxsci/kfu215. Epub 2014 Oct 10.
• [369] Cannabidiol Reduces Leukemic Cell Size - But Is It Important?. Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.
• [370] Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
• [371] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [372] Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
• [373] Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
• [374] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [375] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [376] NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
• [377] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [378] Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
• [379] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [380] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [381] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [382] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [383] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [384] Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
• [385] Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
• [386] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [387] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [388] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [389] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [390] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [391] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [392] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [393] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [394] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [395] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [396] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [397] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [398] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [399] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [400] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [401] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [402] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [403] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [404] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [405] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [406] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [407] Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells. Int J Gynecol Cancer. 2006 May-Jun;16(3):1321-9.
• [408] Pattern of expression of apoptosis and inflammatory genes in humans exposed to arsenic and/or fluoride. Sci Total Environ. 2010 Jan 15;408(4):760-7. doi: 10.1016/j.scitotenv.2009.11.016. Epub 2009 Dec 4.
• [409] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [410] AS3MT facilitates NLRP3 inflammasome activation by m(6)A modification during arsenic-induced hepatic insulin resistance. Cell Biol Toxicol. 2023 Oct;39(5):2165-2181. doi: 10.1007/s10565-022-09703-7. Epub 2022 Feb 28.
• [411] Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
• [412] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [413] Pterostilbene attenuates RIPK3-dependent hepatocyte necroptosis in alcoholic liver disease via SIRT2-mediated NFATc4 deacetylation. Toxicology. 2021 Sep;461:152923. doi: 10.1016/j.tox.2021.152923. Epub 2021 Aug 30.
• [414] Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 Jul;37(7):863-872. doi: 10.1002/jat.3435. Epub 2017 Jan 31.
• [415] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [416] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [417] The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1400-9. doi: 10.1152/ajpregu.00781.2006. Epub 2007 Jun 13.
• [418] Organochloride pesticides modulated gut microbiota and influenced bile acid metabolism in mice. Environ Pollut. 2017 Jul;226:268-276.
• [419] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [420] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [421] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [422] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [423] Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med Cell Longev. 2018 Mar 18;2018:1482795. doi: 10.1155/2018/1482795. eCollection 2018.
• [424] Inhibitory effect of PXR on ammonia-induced hepatocyte autophagy via P53. Toxicol Lett. 2018 Oct 1;295:153-161. doi: 10.1016/j.toxlet.2018.06.1066. Epub 2018 Jun 14.
• [425] TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
• [426] Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.
• [427] A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
• [428] Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
• [429] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [430] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [431] Role of transporter genes in cisplatin resistance. In Vivo. 2008 May-Jun;22(3):279-83.
• [432] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [433] Marine biogenics in sea spray aerosols interact with the mTOR signaling pathway. Sci Rep. 2019 Jan 24;9(1):675.
• [434] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [435] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [436] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [437] Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. Oncotarget. 2014 Dec 30;5(24):12891-907.
• [438] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [439] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [440] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [441] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [442] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [443] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [444] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [445] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [446] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [447] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [448] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [449] Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther. 2007 Mar;6(3):1031-8. doi: 10.1158/1535-7163.MCT-06-0643. Epub 2007 Mar 5.
• [450] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [451] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [452] An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
• [453] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [454] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [455] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [456] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [457] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [458] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [459] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [460] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [461] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [462] PLK1 targets NOTCH1 during DNA damage and mitotic progression. J Biol Chem. 2019 Nov 22;294(47):17941-17950. doi: 10.1074/jbc.RA119.009881. Epub 2019 Oct 9.